AU7328891A - C4 binding protein fusion proteins - Google Patents

C4 binding protein fusion proteins

Info

Publication number
AU7328891A
AU7328891A AU73288/91A AU7328891A AU7328891A AU 7328891 A AU7328891 A AU 7328891A AU 73288/91 A AU73288/91 A AU 73288/91A AU 7328891 A AU7328891 A AU 7328891A AU 7328891 A AU7328891 A AU 7328891A
Authority
AU
Australia
Prior art keywords
c4bp
protein
polypeptide
human
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73288/91A
Other languages
English (en)
Inventor
Theresa R. Liu
Mark P. Pasek
Gunther Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU7328891A publication Critical patent/AU7328891A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU73288/91A 1990-01-26 1991-01-28 C4 binding protein fusion proteins Abandoned AU7328891A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47088890A 1990-01-26 1990-01-26
US470888 1990-01-26

Publications (1)

Publication Number Publication Date
AU7328891A true AU7328891A (en) 1991-08-21

Family

ID=23869471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73288/91A Abandoned AU7328891A (en) 1990-01-26 1991-01-28 C4 binding protein fusion proteins

Country Status (5)

Country Link
EP (1) EP0465633A1 (fr)
JP (1) JPH04506460A (fr)
AU (1) AU7328891A (fr)
CA (1) CA2049964A1 (fr)
WO (1) WO1991011461A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
DK0503648T3 (da) * 1991-03-12 2000-10-30 Biogen Inc CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
WO1999044625A1 (fr) 1998-03-03 1999-09-10 John Hopkins University Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement
DE19980721D2 (de) * 1998-04-15 2001-03-29 Wolfgang Bergter CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion
AU4770300A (en) * 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
EP1483397A4 (fr) * 2002-02-11 2005-06-01 Univ Pennsylvania Molecules oligomeriques et leurs applications
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
US20070092933A1 (en) * 2002-08-14 2007-04-26 Avidis Sa Production of multimeric fusion proteins using a c4bp scaffold
CN1867588A (zh) * 2003-08-12 2006-11-22 阿维迪斯公司 包含c4bp核心蛋白质和单体抗原的产品及其用途
WO2005051414A1 (fr) * 2003-11-26 2005-06-09 Avidis Sa Utilisation de la zone nucleique c4bp comme agoniste de cd40
WO2005077976A2 (fr) * 2004-02-13 2005-08-25 Avidis Sa Domaines bispirales
WO2005115436A1 (fr) 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
EP1790358A1 (fr) 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Constructions protéiques concues pour cibler et lyser des cellules
EP1795540A1 (fr) * 2005-11-30 2007-06-13 Imaxio Complexes multiples d'antigènes et d'un adjuvant
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2557089A2 (fr) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions et procédés d'immunomodulation
US10342863B2 (en) 2015-03-24 2019-07-09 Fred Hutchinson Cancer Research Center Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof
EP3373952A4 (fr) 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center Leurres nkg2d
US11707505B2 (en) 2019-11-15 2023-07-25 King Faisal Specialist Hospital & Research Centre VCP and factor H as viral entry inhibitors

Also Published As

Publication number Publication date
JPH04506460A (ja) 1992-11-12
WO1991011461A1 (fr) 1991-08-08
EP0465633A1 (fr) 1992-01-15
CA2049964A1 (fr) 1991-07-27

Similar Documents

Publication Publication Date Title
AU7328891A (en) C4 binding protein fusion proteins
EP0394827A1 (fr) Polypeptides chimériques de CD4-immunoglobuline
Zettlmeissl et al. Expression and characterization of human CD4: immunoglobulin fusion proteins
US5817767A (en) Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
EP0325262B1 (fr) Gènes clonés encodant des protéines fusionnées Ig-CD4 et leur utilisation
US5116964A (en) Hybrid immunoglobulins
US6406697B1 (en) Hybrid immunoglobulins
US20060229435A1 (en) Lymphocyte homing receptors
NZ226040A (en) T-cell specific antigens, dna and pharmaceutical compositions
JP2003089654A (ja) リンパ球機能関連抗原３のｃｄ２結合ドメイン
EP1340769B1 (fr) Chimères de CD4-gamma2 et de CD4-IgG2
US7825085B2 (en) Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
CN102690354B (zh) 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统
AU690421B2 (en) Anti-inflammatory CD14 peptides
EP2096121A1 (fr) Peptides antiviraux comprenant des signaux de fixation de lipides et leurs procédés d'utilisation
CA2063593A1 (fr) Constructs de fusion de la gelsoline multimerique
WO1992013559A1 (fr) CHIMERES DE CD4-GAMMA1 ET DE CD4-IgG1
IL91070A (en) Cytotoxic agents against certain viral infections
US7070991B2 (en) Cells expressing a CD4-IgG2 chimeric heterotetramer
CA2823297A1 (fr) Proteines mic non naturelles
JPH06502541A (ja) フォン・ウィルブランド因子の治療断片
AU626007C (en) DNA sequences, recombinant DNA molecules and processes for producing soluble T4 proteins
AU623924B2 (en) Cytotoxic agent against specific virus infection
Egerer et al. The Prevention of HIV Infection with Viral Entry Inhibitors